Loading viewer...
annual_report
Format: PDF annual_report
Alkem Laboratories' FY 2023-24 annual report details the company's strategic expansion across chronic diseases, acute segments, and emerging therapeutic areas. Key initiatives include the launch of Cetuxa biosimilar, entry into ophthalmology and CDMO services, and portfolio optimization driving productivity-led growth. The report highlights financial performance and commitment to innovation in the pharmaceutical sector since the company's 1973 inception.
Alkem Laboratories 2017-18 Annual Report
annual_reportannual_report
236 Pages
annual_report
181 Pages
Aarti Industries
Accelleron 2025 Corporate Governance Report
annual_reportannual_report
15 Pages
Accelleron Industries
annual_report
Boliden
ADP Annual Report 2018 Form 10-K
annual_reportannual_report
139 Pages
Automatic Data Processing